openPR Logo

Press Releases from (1 total)

Benign prostatic hyperplasia: BPH drugs versus Dr Allen’s Device

The Global Treatment Market of Benign prostatic hyperplasia (BPH) was valued at $10,688.72 million in 2017 and is projected to reach $20,096.68 million by 2025 at a CAGR of 8.1% from 2018 to 2025. Thermobalancing therapy with Dr Allen’s Device was patented by the United States Patent and Trademark Office. Over a decade, thousands of men with BPH used or are using this non-invasive and side-effects free Dr Allen’s Device.

Go To Page:   1 2 3 4 5 6 7 8 9 10